🇺🇸 FDA
Pipeline program

FX006

HSC-MS-18-0672

Phase 2 small_molecule completed

Quick answer

FX006 for Trochanteric Bursitis is a Phase 2 program (small_molecule) at Pacira BioSciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Pacira BioSciences
Indication
Trochanteric Bursitis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials